Contemporary Context of Drug-Eluting Stents in Brazil: A Cost Utility Study

Conclusion. DES is not a good value for money in SUS perspective, despite its benefit in reducing target vessel revascularization. Since the cost-effectiveness of DES is mainly driven by the stents’ cost difference, they should cost less than twice the BMS price to become a cost-effective alternative.

Source: Medical Decision Making - September 28, 2016 Category: Health Management Authors: Stella, S. F., Gehling Bertoldi, E., Polanczyk, C. A. Tags: Original Articles Source Type: research